Review
doi: 10.1016/j.cpet.2019.08.006.
18F-Fludeoxyglucose PET/Computed Tomography for Assessing Tumor Response to Immunotherapy and Detecting Immune-Related Side Effects: A Checklist for the PET Reader
Affiliations
- PMID: 31735296
- DOI: 10.1016/j.cpet.2019.08.006
Item in Clipboard
Review
18F-Fludeoxyglucose PET/Computed Tomography for Assessing Tumor Response to Immunotherapy and Detecting Immune-Related Side Effects: A Checklist for the PET Reader
PET Clin.
2020 Jan.
Abstract
After a short summary of the biological basis of the immune checkpoint inhibitors used for the treatment of nonhematologic solid tumors, the issues of pseudoprogression, hyperprogression, and immune-related side effects are discussed as well as their implications for patient management. Recommendations are provided for performing 18F-Fludeoxyglucose PET scanning, assessing tumor response, and reporting immune-related side effects, with representative clinical cases.
Keywords: FDG; Hyperprogression; Immune-related side effects; Immunotherapy; PET; Pseudoprogression; Therapy monitoring.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):238-250. doi: 10.1007/s00259-018-4171-4. Epub 2018 Oct 5. Eur J Nucl Med Mol Imaging. 2019. PMID: 30291373 Free PMC article. Review.
-
18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond.PET Clin. 2020 Jan;15(1):11-22. doi: 10.1016/j.cpet.2019.08.007. PET Clin. 2020. PMID: 31735298 Review.
-
Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas.PET Clin. 2020 Jan;15(1):23-34. doi: 10.1016/j.cpet.2019.08.011. PET Clin. 2020. PMID: 31735299 Review.
-
Immunotherapy-related adverse effects on 18F-FDG PET/CT imaging.Br J Radiol. 2020 Jul;93(1111):20190832. doi: 10.1259/bjr.20190832. Epub 2020 Feb 27. Br J Radiol. 2020. PMID: 32105505 Free PMC article.
-
18 F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy.J Med Imaging Radiat Oncol. 2022 Jun;66(4):483-494. doi: 10.1111/1754-9485.13390. Epub 2022 Feb 22. J Med Imaging Radiat Oncol. 2022. PMID: 35191204 Free PMC article.
Cited by
-
PET/CT variants and pitfalls in malignant melanoma.Cancer Imaging. 2022 Jan 4;22(1):3. doi: 10.1186/s40644-021-00440-4. Cancer Imaging. 2022. PMID: 34983677 Free PMC article. Review.
-
Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients.Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2573-2585. doi: 10.1007/s00259-020-05103-3. Epub 2021 Jan 12. Eur J Nucl Med Mol Imaging. 2021. PMID: 33432374
-
18F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital.Diagnostics (Basel). 2021 Jul 1;11(7):1198. doi: 10.3390/diagnostics11071198. Diagnostics (Basel). 2021. PMID: 34359281 Free PMC article.
-
Diagnostic impact of 18F-FDG PET/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy.Clin Transl Oncol. 2022 Oct;24(10):1903-1913. doi: 10.1007/s12094-022-02840-9. Epub 2022 May 20. Clin Transl Oncol. 2022. PMID: 35594002
-
A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment.Clin Transl Oncol. 2021 Mar;23(3):434-449. doi: 10.1007/s12094-020-02442-3. Epub 2020 Jul 4. Clin Transl Oncol. 2021. PMID: 32623581 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
